论文部分内容阅读
目的观察奥丹西酮在原发性肝癌患者体内的药物动力学特性。方法8名接受顺铂 +5 -氟尿嘧啶化疗的原发性肝癌患者单次和多次口服16mg 奥丹西酮后 ,应用反相高效液相色谱法测定血浆药物浓度 ,并用PKBP -N1程序在计算机上拟合。结果奥丹西酮表现为二房室模型,其单剂量和多剂量口服主要药动学参数分别为 :T1/2β 为4.3±0.5h和5.7±0.7h(P<0.01),Cmax 为42.6±3.8μg/L和49.2±2.3μg/L(P<0.05),Tmax 为1.8±0.2h和1.8±0.1h,AUC0～∞为643.2±84.7μg/h·L和833.4±96.7μg/L·h(P<0.01)。结论原发性肝癌患者多次口服奥丹西酮后与单次口服相比 ,体内有蓄积现象 ,消除能力下降 ,生物利用度升高
Objective To observe the pharmacokinetics of ondansetron in patients with primary liver cancer. METHODS: Eight patients with primary liver cancer undergoing chemotherapy with cisplatin and 5-fluorouracil were treated with ondansetron 16 mg once or several times. Plasma drug concentrations were determined by reversed-phase high-performance liquid chromatography and the PKBP-N1 program was used in the computer. Fit on. Results Ondansetron showed a two-compartment model. The main pharmacokinetic parameters of single-dose and multiple-dose oral administration were: T1/2β was 4.3±0.5h and 5.7±0.7h (P<0.01), and Cmax was 42.6±3.8. Μg/L and 49.2±2.3μg/L (P<0.05), Tmax was 1.8±0.2h and 1.8±0.1h, AUC0～∞ was 643.2±84.7μg/h·L and 833.4±96.7μg/L·h ( P<0.01). Conclusion After multiple oral ondansetron administration in patients with primary liver cancer, there is accumulation phenomenon in the body compared with single oral administration. The elimination ability decreases, and the bioavailability increases.